GlassScriptPhysician profile
Kimlien T Nguyen
NPI 1851774566
$5,635.16
in general payments reported to CMS, 2019-2025
29 companies · $854 in 2025
The $854 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $949 · 2022: $1,021 · 2023: $1,057 · 2024: $1,753 · 2025: $854.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,656 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,656.31 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,168.53 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $786.75 | 2021-2025 | Odomzo, Blu-U, Winlevi |
| Regeneron Healthcare Solutions, INC. | $499.75 | 2021-2025 | Libtayo, Dupixent |
| Journey Medical Corporation | $380.85 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $310.38 | 2024-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $283.11 | 2021-2025 | |
| Lilly USA, LLC | $275.94 | 2021-2024 | Olumiant |
| Genzyme Corporation | $231.93 | 2021-2025 | |
| Dermavant Sciences, INC. | $222.95 | 2023-2024 | Vtama |
| Janssen Biotech, INC. | $197.87 | 2021-2025 | Tremfya, Stelara, Simponi |
| Kerecis Limited | $146.44 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Mayne Pharma Commercial LLC | $129.99 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $124.95 | 2023 | Sotyktu |
| Pfizer INC. | $121.86 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $111.99 | 2024 | Spevigo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $109.09 | 2021 | |
| Verrica Pharmaceuticals INC. | $103.23 | 2024 | Ycanth |
| Galderma Laboratories, L.P. | $78.83 | 2021-2025 | Nemluvio |
| Leo Pharma INC. | $65.74 | 2022-2025 | Adbry |
| Cipher Pharmaceuticals US LLC | $58.47 | 2025 | Spinosad, Natroba |
| Amgen INC. | $41.23 | 2022 | |
| Incyte Corporation | $39.64 | 2021-2023 | Opzelura |
| Organon LLC | $33.60 | 2025 | Vtama |
| Solta Medical, A Division of Bausch Health US, LLC | $24.35 | 2025 | |
| Ucb, INC. | $21.90 | 2025 | Bimzelx |
| Convatec INC. | $20.89 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $20.02 | 2023 | Jublia |
| Nabriva Therapeutics, Plc | $13.43 | 2021 | |
| Hill Dermaceuticals, INC. | $11.45 | 2025 | Tolak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimlien Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.